Serum soluble TWEAK levels in non-alcoholic fatty liver disease

ASİL, Mehmet; DEMİR, ALİ; YOLAÇAN, Ramazan; kayar, yusuf; Dertli, Ramazan; Polat, Hakki; ATASEVEN, Hüseyin; ünver, nurcan; Keskin, Muharrem; UYSAL, SALIHA; biyik, murat

doi:10.5455/annalsmedres.2019.05.248

Serum soluble TWEAK levels in non-alcoholic fatty liver disease

Annals of Medical Research

2 1

Yıl: 2019 Cilt: 26 Sayı: 8 Sayfa Aralığı: 1594 - 1599 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2019.05.248 İndeks Tarihi: 09-01-2020

Serum soluble TWEAK levels in non-alcoholic fatty liver disease

Öz:

Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. The exact pathogenesis of NAFLD hasnot been fully elucidated. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of TNF superfamily and it hasbeen implicated in the pathogenesis of several diseases including liver inflammation and fibrosis. Current study was conducted toevaluate serum sTWEAK levels in patients with NAFLD.Material and Methods: Seventeen patients with biopsy proven non-alcoholic steatohepatitis (NASH), 22 patients with simplehepatosteatosis and 30 healthy controls were included in the study and serum sTWEAK concentrations were measured usingcommercial ELISA kits.Results: Mean serum sTWEAK concentration was significantly lower in the NASH group when compared to the simple hepatosteatosisgroup and healthy controls (199.6±101.2 pg/mL, 246.1±65.7 pg/mL and 277.6±117.6 pg/mL respectively, p=0.029). ROC analysesfor sTWEAK to differentiate NASH patients from healthy controls and from simple hepatosteatosis revealed that AUC for sTWEAKwas 0.712 (%95 CI, 0.543-0.880). For the specified cut off value, 171.1 pg/mL positive and negative predictive values calculated were64.3% and 85.5% respectively.Conclusion: Serum sTWEAK concentration is decreasedin patients with NASH when compared to patients with simple hepatosteatosisand healthy controls.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90.
2. Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011;5:189-200.
3. Masarone M, Rosato V, Dallio M, at al. role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev 2018:11;2018:9547613.
4. Asil M, Dertli R., Biyik, et al. Dynamic thiol-disulfide homeostasis is disturbed in patients with non-alcoholic fatty liver disease. Laboratoriums Medizin 2017;42:31-38.
5. Meli R, Mattace RG, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014:23;5:177.
6. Burkly LC, Michaelson JS, Hahm K, et al. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/ Fn14 pathway in health and disease.Cytokine. 2007;40:1- 16.
7. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis.Immunity. 2001;15:837-46.
8. Novoyatleva T, Sajjad A, Engel FB. TWEAK-Fn14 cytokinereceptor axis: a new player of myocardial remodeling and cardiac failure. Front Immunol. 2014;11:5-50.
9. Turkmen K, Tonbul HZ, Erdur FM, et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol. 2013;14:144.
10. Choe JY, Kim SK. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus. Inflamm Res. 2016;65:479-88.
11. Kawashima R, Kawamura YI, Oshio T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology 2011;141:2119-29.
12. Wilhelm A, Shepherd EL, Amatucci A, et al. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation. J Pathol. 2016;239:109-21.
13. Affò S, Dominguez M, Lozano JJ, et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut. 2013;62:452- 60.
14. Asil M, Dertli R. Serum soluble TWEAK levels are decreased in treatment naive noncirrhotic chronic hepatitis B patients. Medicine (Baltimore). 2016;95:e4763.
15. Eryılmaz MA, Baktık S, Ay S, et al. Incidence of pathologies detected by abdominal ultrasonography screening. Selçuk Tıp Derg 2014;30: 19-22.
16. Feng SLY, Guo Y, Factor VM, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000;156:1253–61.
17. Jakubowski A, Ambrose C, Parr M, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005;115:2330-40.
18. Lozano-Bartolomé J, Llauradó G, Rodriguez MM, et al. Reduced circulating levels of sTWEAK are associated with NAFLD and may affect hepatocyte triglyceride accumulation. Int J Obes (Lond). 2016;40:1337-45.
19. Karaca G, Swiderska-Syn M, Xie G, et al. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS One 2014;9:e83987.
20. Wilhelm A, Shepherd EL, Amatucci A, et al. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation. J Pathol 2016;239:109-21.
21. Jelić-Ivanović Z, Bujisić N, Spasić S, et al.Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 2009;42:1381-6.
22. Moreno JA, Dejouvencel T, Labreuche J, et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010;30:1253- 62.
23. Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAKare decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008;199:440-4.
24. Carrero JJ1, Ortiz A, Qureshi AR, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110-8.

APA	Dertli R, biyik m, YOLAÇAN R, Keskin M, kayar y, UYSAL S, ATASEVEN H, Polat H, ünver n, DEMİR A, ASİL M (2019). Serum soluble TWEAK levels in non-alcoholic fatty liver disease. , 1594 - 1599. 10.5455/annalsmedres.2019.05.248
Chicago	Dertli Ramazan,biyik murat,YOLAÇAN Ramazan,Keskin Muharrem,kayar yusuf,UYSAL SALIHA,ATASEVEN Hüseyin,Polat Hakki,ünver nurcan,DEMİR ALİ,ASİL Mehmet Serum soluble TWEAK levels in non-alcoholic fatty liver disease. (2019): 1594 - 1599. 10.5455/annalsmedres.2019.05.248
MLA	Dertli Ramazan,biyik murat,YOLAÇAN Ramazan,Keskin Muharrem,kayar yusuf,UYSAL SALIHA,ATASEVEN Hüseyin,Polat Hakki,ünver nurcan,DEMİR ALİ,ASİL Mehmet Serum soluble TWEAK levels in non-alcoholic fatty liver disease. , 2019, ss.1594 - 1599. 10.5455/annalsmedres.2019.05.248
AMA	Dertli R,biyik m,YOLAÇAN R,Keskin M,kayar y,UYSAL S,ATASEVEN H,Polat H,ünver n,DEMİR A,ASİL M Serum soluble TWEAK levels in non-alcoholic fatty liver disease. . 2019; 1594 - 1599. 10.5455/annalsmedres.2019.05.248
Vancouver	Dertli R,biyik m,YOLAÇAN R,Keskin M,kayar y,UYSAL S,ATASEVEN H,Polat H,ünver n,DEMİR A,ASİL M Serum soluble TWEAK levels in non-alcoholic fatty liver disease. . 2019; 1594 - 1599. 10.5455/annalsmedres.2019.05.248
IEEE	Dertli R,biyik m,YOLAÇAN R,Keskin M,kayar y,UYSAL S,ATASEVEN H,Polat H,ünver n,DEMİR A,ASİL M "Serum soluble TWEAK levels in non-alcoholic fatty liver disease." , ss.1594 - 1599, 2019. 10.5455/annalsmedres.2019.05.248
ISNAD	Dertli, Ramazan vd. "Serum soluble TWEAK levels in non-alcoholic fatty liver disease". (2019), 1594-1599. https://doi.org/10.5455/annalsmedres.2019.05.248

APA	Dertli R, biyik m, YOLAÇAN R, Keskin M, kayar y, UYSAL S, ATASEVEN H, Polat H, ünver n, DEMİR A, ASİL M (2019). Serum soluble TWEAK levels in non-alcoholic fatty liver disease. Annals of Medical Research, 26(8), 1594 - 1599. 10.5455/annalsmedres.2019.05.248
Chicago	Dertli Ramazan,biyik murat,YOLAÇAN Ramazan,Keskin Muharrem,kayar yusuf,UYSAL SALIHA,ATASEVEN Hüseyin,Polat Hakki,ünver nurcan,DEMİR ALİ,ASİL Mehmet Serum soluble TWEAK levels in non-alcoholic fatty liver disease. Annals of Medical Research 26, no.8 (2019): 1594 - 1599. 10.5455/annalsmedres.2019.05.248
MLA	Dertli Ramazan,biyik murat,YOLAÇAN Ramazan,Keskin Muharrem,kayar yusuf,UYSAL SALIHA,ATASEVEN Hüseyin,Polat Hakki,ünver nurcan,DEMİR ALİ,ASİL Mehmet Serum soluble TWEAK levels in non-alcoholic fatty liver disease. Annals of Medical Research, vol.26, no.8, 2019, ss.1594 - 1599. 10.5455/annalsmedres.2019.05.248
AMA	Dertli R,biyik m,YOLAÇAN R,Keskin M,kayar y,UYSAL S,ATASEVEN H,Polat H,ünver n,DEMİR A,ASİL M Serum soluble TWEAK levels in non-alcoholic fatty liver disease. Annals of Medical Research. 2019; 26(8): 1594 - 1599. 10.5455/annalsmedres.2019.05.248
Vancouver	Dertli R,biyik m,YOLAÇAN R,Keskin M,kayar y,UYSAL S,ATASEVEN H,Polat H,ünver n,DEMİR A,ASİL M Serum soluble TWEAK levels in non-alcoholic fatty liver disease. Annals of Medical Research. 2019; 26(8): 1594 - 1599. 10.5455/annalsmedres.2019.05.248
IEEE	Dertli R,biyik m,YOLAÇAN R,Keskin M,kayar y,UYSAL S,ATASEVEN H,Polat H,ünver n,DEMİR A,ASİL M "Serum soluble TWEAK levels in non-alcoholic fatty liver disease." Annals of Medical Research, 26, ss.1594 - 1599, 2019. 10.5455/annalsmedres.2019.05.248
ISNAD	Dertli, Ramazan vd. "Serum soluble TWEAK levels in non-alcoholic fatty liver disease". Annals of Medical Research 26/8 (2019), 1594-1599. https://doi.org/10.5455/annalsmedres.2019.05.248